You are here

Orilissa

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

Endpoints

Teva Pharmaceuticals

Flag link:

Myovant Squares Off with AbbVie On Endometriosis Treatment

Myovant Squares Off with AbbVie On Endometriosis Treatment

Motley Fool

Myovant Sciences

clinical trials

Flag link:

2 Things Investors Are Missing About AbbVie

2 Things Investors Are Missing About AbbVie

Motley Fool

Flag link:

Why Abbvie Is Down 5% in 2018 So Far

Why Abbvie Is Down 5% in 2018 So Far

Motley Fool

Flag link:

AbbVie's Orilissa makes its uterine fibroids case with double phase 3 win

AbbVie's Orilissa makes its uterine fibroids case with double phase 3 win

Fierce Pharma

uterine fibroids

Flag link:

AbbVie's new endometriosis drug to cost $10K per year

AbbVie's new endometriosis drug to cost $10K per year

Biopharma Dive

Flag link:

AbbVie wins FDA approval for oral treatment for endometriosis pain

AbbVie wins FDA approval for oral treatment for endometriosis pain

Marketwatch

Flag link: